logo-loader
viewAvacta Group PLC

Avacta's CSO to Present at Major US Conference

/**/ sup{font-size:80%}p{margin-right:0cm;margin-left:0cm;font-size:10.0pt;font-family:"Times","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bd{size:595.0pt 842.0pt;margin:69.25pt 42.15pt 49.65pt 70.9pt;}div.bd{}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:9.2pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:115%}span.ct{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: right}span.cr{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif"}p.cx{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: center}p.cy{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: center}p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm; text-align: center}span.cn{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black} p.da{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: justify; text-justify: inter-ideograph}p.db{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";text-align:justify;text-justify:inter-ideograph}span.cj{font-size:10.0pt;font-family:"Arial","sans-serif"}span.ck{background:white}p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 205.55pt; margin-right: 9.2pt; margin-top: 0cm}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%}table.de{width:440.9pt;margin-left:-5.4pt;border-collapse:collapse}td.cb{width:230.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.df{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm}span.cf{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black} p.dg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:14.2pt;margin-bottom:.0001pt;line-height:115%}p.dh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 9.2pt; margin-top: 0cm}td.by{width:188.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.di{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:9.2pt;margin-bottom:0cm; margin-left:14.2pt;margin-bottom:.0001pt;line-height:115%}span.ca{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif";color:black}span.bx{font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif";color:black}span.bw{font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif"}p.dj{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:9.2pt;margin-bottom: 0cm;margin-left:14.2pt;margin-bottom:.0001pt;line-height:115%}p.dk{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";line-height: 115%; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm; text-decoration: underline}span.dl{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;color: black; font-family: "Arial","sans-serif"; font-size: 10.0pt; line-height: 115%; text-decoration: none} p.dm{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm}p.dn{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:14.2pt;margin-bottom:.0001pt}span.br{font-size: 10.0pt;font-family:"Arial","sans-serif"}span.bp{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:black}p.do{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 0cm; margin-left: 14.2pt; margin-right: 0cm; margin-top: 0cm; text-decoration: underline}span.bn{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:windowtext}span.bm{font-size: 10.0pt;line-height:115%;font-family:"Arial","sans-serif";color:windowtext}p.dp{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 10.0pt; margin-left: 14.2pt; margin-right: 9.2pt; margin-top: 0cm}span.bk{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif"}p.dq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-right: 9.2pt} p.dr{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-right:9.2pt;line-height:115%}p.ds{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;line-height:115%}span.bg{font-size: 10.0pt;line-height:115%;font-family:"Arial","sans-serif";color:black}span.be{color: blue; text-decoration: underline} /**/
RNS Number : 8708B
Avacta Group PLC
12 June 2019
 

 

12 June 2019

Avacta Group plc

("Avacta", the "Company" or the "Group")

 

Avacta's Chief Scientific Officer to Present at Major US Conference

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Next Generation Protein Therapeutics & Bioconjugates conference in San Francisco, California on 19 June 2019.

Dr Basran's presentation, 'Affimer Therapeutics: A Novel Human Scaffold for the Generation of Bi-specific Molecules', will give an overview of the benefits of using Affimer technology to generate bispecific drug molecules.

Bispecific therapy - single molecules that engage with two drug targets simultaneously - is a major area of focus in large pharma immuno-oncology programmes.  Avacta has highlighted bispecifics as a key element of its therapeutic pipeline strategy, alongside the development of its novel tumour microenvironment activated drug conjugates.

Dr Basran's presentation will highlight the stability, solubility and ease of manufacturing functional Affimer bispecifics incorporating Avacta's proprietary serum half-life extension technology (Affimer XTTM), as well as PD-L1 and LAG-3 Affimer inhibitors.

- Ends -

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Giles Rolls - Corporate Finance

Tim Redfern - ECM

 

WG Partners (Joint Broker)

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Turner Pope Investments

James Pope / Ben Turner

 

Yellow Jersey PR (Financial Media and IR)

Sarah Hollins

Harriet Jackson

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0) 203 621 4120

www.turnerpope.com

 

 

Tel: +44 (0)7764 947 137

Tel: +44 (0)7544 275 882

[email protected]

 

Tel: +44 (0)7787 502 947

[email protected] 

 

 

 

 

About Avacta Group plc - www.avacta.com

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $100bn despite their shortcomings.  Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes.  Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics. 

 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRACKDDKPBKDOAD

Quick facts: Avacta Group PLC

Price: 16.25

Market: AIM
Market Cap: £18.88 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Immotion signs deal with Aspro Parks

Headlines from the Proactive UK newsroom. Immotion (LON:IMMO) is to put one of its virtual reality entertainment pods in Spanish leisure operator Aspro Parks’ Blue Planet Aquarium in Cheshire.  Aspro’s one of the largest European operators of leisure parks and centres with 68 locations...

1 week, 2 days ago